Cardiome Development AG, a subsidiary of Cardiome Pharma Corp., has entered into an agreement with Biospifar SA, to sell and distribute Brinavess (vernakalant intravenous) exclusively in Colombia. Under the terms of the agreement, Biospifar SA has agreed to specific annual commercial goals for Brinavess.

Financial details of the agreement have not been disclosed.

“We are delighted to have entered into this commercialization agreement with Biospifar and continue Brinavess availability in the Colombian market,” said Karim Lalji, Cardiome’s chief commercial officer. “This agreement reinforces Cardiome’s commitment to have Brinavess available to other markets beyond Europe.”

“We are pleased to have partnered with Cardiome to sell Brinavess in Colombia,” said Fabio Ospina, Biospifar’s founder and general director. “Brinavess will be a great addition to our line of hospital cardiovascular and intensive care products and provide our customers another option for the management of acute onset atrial fibrillation.”

In 2011, the size of the Colombian pharmaceutical market was estimated at $3.5B, of which the hospital sector comprises $1.3B.

Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world.

Biospifar’s mission is to commercialize specialized and biotechnological pharmaceutical products for niche markets, devices, medical supplies and medical instruments to the health and hospital sectors in Colombia.